Compare BioNano Genomics Inc (BNGO) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Transocean Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.31M), while Transocean Ltd trades at $5.81 (market cap $6.39B). The key difference: Transocean Ltd is far larger — about 480.1× BioNano Genomics Inc's market cap, and Transocean Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | RIG | |
|---|---|---|
Market Cap | $13.31M | $6.39B |
Sector | Health | Technology |
52-Week High | $4.92 | $7.58 |
52-Week Low | $1.06 | $2.80 |
Enterprise Value | $15.92M | $11.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16, up 5.45% today, with a bullish technical signal from moving averages. The company shows improving financial trends with revenue stabilizing around $29M annually and narrowing losses from -$232M in 2023 to -$26M in 2025. Recent earnings beats and positive news flow around optical genome mapping adoption support momentum.
While BNGO demonstrates operational improvement and analyst support (57% buy ratings), the stock faces significant risks including persistent negative profitability, cash burn requiring ongoing financing, and competitive pressures in genomic technology. The current valuation appears attractive on P/S and P/B metrics but reflects the company's pre-profitability stage.
Transocean (RIG) trades at $5.26, up 1.94% with neutral technical signals. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses improving to -$1.7B. Recent Q2 2026 earnings beat expectations with $0.03 EPS, and the company secured a significant $1B+ contract with Equinor, boosting long-term visibility. Analyst sentiment is divided with 39% buy ratings, while institutional activity shows mixed positioning with recent large acquisitions by Elliott Investment Management.
RIG presents a turnaround opportunity with improving operational metrics and contract wins, but significant execution risks remain. The pending Valaris merger could create synergies, though current negative profitability and high debt require careful monitoring. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial losses against the company's market position and backlog growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
